Suggestions
Joseph Sullivan
Biotechnology Executive
Joseph Sullivan is an experienced pharmaceutical and biotechnology executive who currently serves as the Chief Executive Officer of AuraVax Therapeutics, Inc., a position he has held since March 2023.12
Professional Background
Sullivan brings over 30 years of experience in the pharmaceutical and biotechnology industries, with expertise in commercializing vaccines and biologics.2 His career highlights include:
- Chief Commercial Officer at Nature's Toolbox (NTx) from 2020 to 20233
- Co-founder of Gypsy Basin Genomics, Inc. from 2019 to 20233
- Senior Vice President of Business Development at IMV Inc. from 2018 to 20203
- Various executive roles at Merck & Co, Inc. over a 27-year period, including:
- Executive Director of Vaccine Partner Strategy and Implementation Lead
- Executive Director of the New Vaccines Product Group
- Executive Director of the HPV Franchise
- Senior Director of the Dermatology Franchise
- Senior Director of the Respiratory Franchise3
Achievements
During his tenure at Merck, Sullivan achieved notable successes:
- Managed the introduction of the Gardasil vaccine in the United States1
- Led the growth of Singulair into a multi-billion-dollar business for asthma and allergic rhinitis12
Current Role at AuraVax
As CEO of AuraVax Therapeutics, Sullivan is leading the company's efforts to develop novel immunotherapies for preventing and treating respiratory viruses.4 His responsibilities include:
- Overseeing the company's first clinical studies to evaluate NanoSTING, their lead therapeutic candidate1
- Guiding the commercialization of a new inhaled nasal STING agonist platform called NanoSTING4
- Preparing to file the company's first investigational new drug application for NanoSTING in the field of respiratory disease2
Education
Sullivan holds the following degrees:
- MBA from Cornell University's Johnson Graduate School of Management, specializing in Marketing/Finance34
- Bachelor's Degree in Economics from Hamilton College (1980-1984)3
Joseph Sullivan's extensive experience in pharmaceuticals, drug and vaccine commercialization, and business development positions him well to lead AuraVax Therapeutics in its mission to develop innovative treatments for respiratory diseases.